MedTrace Logo

Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer

NCT05730673 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-02-17

No results posted yet for this study

Summary

This is aPhase II Study of Leronlimab (PRO 140) in combination with Regorafenib in Patients with CCR5+, Microsatellite Stable (MSS), Metastatic Colorectal Cancer (mCRC)

Conditions

Interventions

DRUG

700mg leronlimab weekly dose

leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5

DRUG

80mg Regorafenib at week 1

Regorafenib is a small-molecule multiple kinase inhibitor

DRUG

120mg Regorafenib at week2

Regorafenib is a small-molecule multiple kinase inhibitor

DRUG

160 mg Regorafenib at week 3

Regorafenib is a small-molecule multiple kinase inhibitor

Sponsors & Collaborators

  • Amarex Clinical Research

    collaborator OTHER

  • CytoDyn, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-20
Primary Completion
2023-05-27
Completion
2023-08-10
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05730673 on ClinicalTrials.gov